​

Plus Therapeutics (PSTV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PSTV Stock Forecast

Plus Therapeutics (PSTV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $1.00, with a high of $1.00 and a low of $1.00. This represents a 284.62% increase from the last price of $0.26.

High: $1 Avg: $1 Low: $1 Last Closed Price: $0.26

PSTV Stock Rating

Plus Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

PSTV Price Target Upside V Benchmarks

TypeNameUpside
StockPlus Therapeutics284.62%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts122
Avg Price Target$1.00$1.50$1.50
Last Closing Price$0.26$0.26$0.26
Upside/Downside284.62%476.92%476.92%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2613---4
Dec, 2513---4
Nov, 2522---4
Oct, 2522---4
Sep, 25211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 23, 2026Sean LeeH.C. Wainwright$1.00$0.29244.83%284.62%
Nov 26, 2025Sean LeeH.C. Wainwright$2.00$0.61227.87%669.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 23, 2026H.C. WainwrightBuyBuyhold
Nov 26, 2025H.C. WainwrightBuyBuyhold
Nov 03, 2025H.C. WainwrightBuyBuyhold
Nov 15, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024AscendiantBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-11.91$-4.24$-0.20----
Avg Forecast$-11.06$-4.63$-1.94$-1.49$-1.51$-1.08$0.34
High Forecast$-9.20$-4.19$-1.75$-1.44$-0.72$-0.06$0.37
Low Forecast$-12.67$-5.07$-2.12$-1.53$-2.46$-1.97$0.30
Surprise %7.69%-8.42%-89.69%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$224.00K$4.91M-----
Avg Forecast$1.35M$4.66M$6.36M$4.80M$16.86M$31.09M$73.91M
High Forecast$1.50M$5.00M$6.69M$5.15M$18.08M$33.34M$79.25M
Low Forecast$1.17M$4.32M$6.01M$4.44M$15.62M$28.79M$68.44M
Surprise %-83.40%5.36%-----

Net Income Forecast

$-40M $-31M $-22M $-13M $-4M $5M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-20.84M$-13.32M$-12.98M----
Avg Forecast$-34.75M$-13.32M$-6.07M$-4.67M$-4.99M$-3.20M$1.06M
High Forecast$-28.89M$-13.15M$-5.49M$-4.53M$-2.27M$-199.80K$1.16M
Low Forecast$-39.79M$-15.92M$-6.65M$-4.80M$-7.72M$-6.19M$955.63K
Surprise %-40.03%-113.79%----

PSTV Forecast FAQ

Is Plus Therapeutics stock a buy?

Plus Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Plus Therapeutics is a favorable investment for most analysts.

What is Plus Therapeutics's price target?

Plus Therapeutics's price target, set by 4 Wall Street analysts, averages $1 over the next 12 months. The price target range spans from $1 at the low end to $1 at the high end, suggesting a potential 284.62% change from the previous closing price of $0.26.

How does Plus Therapeutics stock forecast compare to its benchmarks?

Plus Therapeutics's stock forecast shows a 284.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Plus Therapeutics over the past three months?

  • January 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Plus Therapeutics’s EPS forecast?

Plus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.49, marking a 645.00% increase from the reported $-0.2 in 2024. Estimates for the following years are $-1.51 in 2026, $-1.08 in 2027, and $0.34 in 2028.

What is Plus Therapeutics’s revenue forecast?

Plus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.8M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $16.86M, followed by $31.09M for 2027, and $73.91M for 2028.

What is Plus Therapeutics’s net income forecast?

Plus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-4.665M, representing a -64.05% decrease from the reported $-12.978M in 2024. Projections indicate $-4.991M in 2026, $-3.197M in 2027, and $1.06M in 2028.